Vox Markets talks to Jeremy Skillington, chief executive of infectious disease specialist Poolbeg Pharma (POLB ), about a year which has seen its drug development programmes moving forward at pace thanks to its unique capital-light and AI led approach to R&D.
0:47 Stated milestones hit throughout a year of major newsflow for the company, and strengthening the team to advance business development and clinical studies
2:51 Describing the unique “capital light” business model and its advantages
4:07 The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis
9:06 Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023
10:54 What’s next on the road to POLB 001 commercialisation
12:02 The renewed focus on infectious diseases, and government support for infectious disease drug development as part of pandemic preparedness plans
13:43 The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023
16:24 Progress on other drugs in the pipeline, POLB 002 and POLB 003
18:09 Balance sheet strength supporting programmes through to commercialisation
19:01 Seeking out further potential drug candidates
*VIDEO* Poolbeg Pharma year in review: fighting disease with AI
Dec 20, 2022Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.